喘中的皮质类固醇管理:从个人处方者到系统级变化
Vincent Gallub1, Linda Rogers, Boram Kim
1Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Current opinion in pulmonary medicine
|February 10, 2026
概括
在喘中过度使用皮质类固醇,包括全身和吸入形式,导致未被认可的危害. 皮质类固醇管理为减轻喘管理中的这些风险提供了一种策略.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 卫生系统科学 卫生系统科学
背景情况:
- 已知慢性系统性皮质类固醇对喘的不良影响.
- 新出现的数据显示,系统性皮质类固醇 (SCS) 短疗程和高剂量吸入性皮质类固醇 (ICS) 的类似危害.
研究的目的:
- 审查在喘中过度使用皮质类固醇所造成的未被认可的危害.
- 突出皮质类固醇管理作为解决这些危害的战略.
主要方法:
- 在喘中皮质类固醇副作用的最新进展的文献综述.
- 呼吁在喘护理中进行皮质类固醇管理的总结.
- 描述基于系统的策略,以减少皮质类固醇的过度使用.
主要成果:
- 过度使用皮质类固醇,包括SCS和ICS,在喘患者中具有重大健康风险.
- 需要更多地意识到短期和长期使用皮质类固醇的危害.
- 现有有效的策略可以减少皮质类固醇的过度使用.
结论:
- 本综述为初级,急性和专科护理提供者提供了对皮质类固醇相关危害的最新理解.
- 它作为实施个人从业者和基于卫生系统的皮质类固醇管理的指南.
- 促进管理可以通过尽量减少与皮质类固醇相关的不良事件来改善喘治疗.
相关概念视频
Asthma-I: Introduction
3.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.6K
COPD: Management Using Bronchodilators and Corticosteroids
831
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
831
Asthma-III: Symptoms and Complications
3.4K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.4K
Asthma-IV: Diagnostic and Management
3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Asthma: Pathogenesis and Management
1.4K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.4K
Asthma-II: Pathophysiology and Classification
4.4K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.4K


